Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (1174)	9/17/1998 10:41:00 AM
From: BMcV	Respond to of 10280

This is the only insider selling I've seen: biz.yahoo.com SOURCE: Sepracor Inc. Southwell Divorce Mandates Options Exercise MARLBOROUGH, Mass., Sept. 17 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR - news) today reported that David P. Southwell, Executive Vice President and Chief Financial Officer, completed the sale of 165,000 shares of Sepracor common stock. Gross proceeds of approximately $7,000,000 represent shares sold at the request of Mr. Southwell's former wife pursuant to the divorce settlement. The shares were obtained through exercising stock options granted by Sepracor, which have been described in the Company's various SEC filings. The sale of shares will be reported to the Securities and Exchange Commission on Form 4. Sepracor is a specialty pharmaceutical company that develops and commercializes potentially improved versions of widely-prescribed drugs. Referred to as Improved Chemical Entities (''ICE''), Sepracor's ICE(TM) Pharmaceuticals are being developed as proprietary, single-isomer or active- metabolite versions of these leading drugs. ICE Pharmaceuticals are designed to offer meaningful improvements in patient outcome through reduced side effects, increased therapeutic efficacy, improved dosage forms, and in some cases the opportunity for additional indications. To receive a copy of this release or any recent release via fax, call Sepracor's automated news fax line at 1-800-758-5804 ext. 780960. SOURCE: Sepracor Inc. ------------------------------------------------------------------------